Tafalgie_client_23, auteur/autrice sur Tafalgie Therapeutics

Marseille-based biotech launches a new generation of painkillers Marseille-based biotech has just been selected by the European Innovation Council for its molecules as alternatives to opioids.

Tafalgie Therapeutics: an alternative painkiller to opioids Tafalgie Therapeutics is developing a new generation of pain-relieving peptides devoid of the disabling side effects of opioids. This start-up is one of Challenges’ “100 start-ups to invest in in 2024”.

Tafalgie Therapeutics to benefit from the EIC Accelerator Program We are proud to announce that Tafalgie Therapeutics is one of only 47[JS1] European companies (12 of which are French) to have been selected in the November 2023 call for proposals for the European Innovation Council (EIC) “Accelerator” program, which rewards companies displaying excellence in the […]

Tafalgie Therapeutics expands R&D capabilities and moves into new premises Tafalgie Therapeutics, a biopharmaceutical research company specializing in the development of treatments for relieving and preventing acute and chronic pain (inflammatory, postoperative, neuropathic) without adverse effects, is pleased to announce that its teams are today moving to a new site with dedicated research and support […]

Tafalgie Therapeutics will participate in the ‘IPOready’ 2024 program, a pre-IPO program organized by Euronext for the 9th consecutive year Tafalgie Therapeutics, a biopharmaceutical research company specializing in research and innovation for treatments to alleviate and prevent acute and chronic pain (inflammatory, postoperative, neuropathic) without side effects is proud to announce that it has been […]

Aziz Moqrich has been awarded the SATT IMPACT 2022 Prize for his team’s work on the TAFA4 protein Dr Moqrich is Research Director at the IBDM laboratory (part of the CNRS, the French National Center for Scientific Research) and cofounder of Tafalgie Therapeutics. Th award recognizes the major discoveries he and his team have made, […]